Literature DB >> 25252870

Insulin-like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation.

J Steger1, E Füller1, M-P Garcia-Cuellar1, K Hetzner1, R K Slany1.   

Abstract

HOX homeobox proteins are key oncogenic drivers in hematopoietic malignancies. Here we demonstrate that HOXA1, HOXA6 and predominantly HOXA9 are able to induce the production of insulin-like growth factor 1 (Igf1). In chromatin immunoprecipitations, HOXA9 bound directly to the putative promoter and a DNase-hypersensitive region in the first intron of the Igf1 gene. Transcription rates of the Igf1 gene paralleled HOXA9 activity. Primary cells transformed by HOXA9 expressed functional Igf1 receptors and activated the protein kinase Akt in response to Igf1 stimulation, suggesting the existence of an autocrine signaling loop. Genomic deletion of the Igf1 gene by Cre-mediated recombination increased sensitivity toward apoptosis after serum starvation. In addition, the leukemogenic potential of Igf1-negative, HOXA9-transformed cells was impaired, leading to a significant delay in disease development on transplantation into recipient animals.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25252870     DOI: 10.1038/leu.2014.287

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  38 in total

Review 1.  The role of HOX genes in malignant myeloid disease.

Authors:  Elizabeth A Eklund
Journal:  Curr Opin Hematol       Date:  2007-03       Impact factor: 3.284

2.  The homeodomain region controls the phenotype of HOX-induced murine leukemia.

Authors:  Constanze Breitinger; Emanuel Maethner; Maria-Paz Garcia-Cuellar; Robert K Slany
Journal:  Blood       Date:  2012-09-18       Impact factor: 22.113

3.  Effects of insulin-like growth factor-1 on B-cell precursor acute lymphoblastic leukemia.

Authors:  Hiroyuki Yamada; Kazutoshi Iijima; Osamu Tomita; Tomoko Taguchi; Masashi Miharu; Kenichiro Kobayashi; Hajime Okita; Masahiro Saito; Toshiaki Shimizu; Nobutaka Kiyokawa
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

4.  c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells.

Authors:  Jay L Hess; Claudia B Bittner; Deniz T Zeisig; Christian Bach; Uta Fuchs; Arndt Borkhardt; Jon Frampton; Robert K Slany
Journal:  Blood       Date:  2006-02-28       Impact factor: 22.113

5.  IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.

Authors:  Christopher R Jenkins; Olena O Shevchuk; Vincenzo Giambra; Sonya H Lam; Joan M Carboni; Marco M Gottardis; Martin Holzenberger; Michael Pollak; R Keith Humphries; Andrew P Weng
Journal:  Exp Hematol       Date:  2012-05-18       Impact factor: 3.084

Review 6.  The insulin and insulin-like growth factor receptor family in neoplasia: an update.

Authors:  Michael Pollak
Journal:  Nat Rev Cancer       Date:  2012-02-16       Impact factor: 60.716

7.  Frat2 mediates the oncogenic activation of Rac by MLL fusions.

Authors:  Vanessa Walf-Vorderwülbecke; Jasper de Boer; Sarah J Horton; Renée van Amerongen; Natalie Proost; Anton Berns; Owen Williams
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

8.  Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins.

Authors:  Thomas A Milne; Keji Zhao; Jay L Hess
Journal:  Methods Mol Biol       Date:  2009

9.  A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins.

Authors:  T D Littlewood; D C Hancock; P S Danielian; M G Parker; G I Evan
Journal:  Nucleic Acids Res       Date:  1995-05-25       Impact factor: 16.971

10.  Fetal growth and body size genes and risk of childhood acute lymphoblastic leukemia.

Authors:  Anand P Chokkalingam; Catherine Metayer; Ghislaine Scelo; Jeffrey S Chang; Joshua Schiffman; Kevin Y Urayama; Xiaomei Ma; Helen M Hansen; James H Feusner; Lisa F Barcellos; John K Wiencke; Joseph L Wiemels; Patricia A Buffler
Journal:  Cancer Causes Control       Date:  2012-07-28       Impact factor: 2.506

View more
  5 in total

1.  HoxA9 transforms murine myeloid cells by a feedback loop driving expression of key oncogenes and cell cycle control genes.

Authors:  Xiaoxia Zhong; Andreas Prinz; Julia Steger; Maria-Paz Garcia-Cuellar; Markus Radsak; Abderrazzak Bentaher; Robert K Slany
Journal:  Blood Adv       Date:  2018-11-27

Review 2.  Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets.

Authors:  C T Collins; J L Hess
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

3.  HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.

Authors:  Yuqing Sun; Bo Zhou; Fengbiao Mao; Jing Xu; Hongzhi Miao; Zhenhua Zou; Le Tran Phuc Khoa; Younghoon Jang; Sheng Cai; Matthew Witkin; Richard Koche; Kai Ge; Gregory R Dressler; Ross L Levine; Scott A Armstrong; Yali Dou; Jay L Hess
Journal:  Cancer Cell       Date:  2018-09-27       Impact factor: 31.743

Review 4.  Deregulation of the HOXA9/MEIS1 axis in acute leukemia.

Authors:  Cailin T Collins; Jay L Hess
Journal:  Curr Opin Hematol       Date:  2016-07       Impact factor: 3.284

5.  Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions.

Authors:  Alessandro Ottaiano; Luisa Circelli; Mariachiara Santorsola; Giovanni Savarese; Daniela Fontanella; Valerio Gigantino; Annabella Di Mauro; Maurizio Capuozzo; Silvia Zappavigna; Angela Lombardi; Francesco Perri; Marco Cascella; Vincenza Granata; Maurizio Capuozzo; Guglielmo Nasti; Michele Caraglia
Journal:  Mol Oncol       Date:  2021-11-19       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.